Objective: The aim of this study is determine and compare improvement of hydronephrosis, renal function, and operative outcome between laparoscopıc and open pyeloplasty in adults. Material and methods: Sixty-five adult patients with primary ureteropelvic junction obstruction (UPJO) underwent pyeloplasty between January 2014 and September 2020. Thirty-four patients had laparoscopıc pyeloplasty (LP), 31 patients had open pyeloplasty (OP). In this retrospective study demographics, differential renal function (DRF), hydronephrosis, anteroposterior diameter of pelvis renalis (APD) and operative outcomes: operation time, blood loss, complications, hospital stay, etiology, analgesic requirement, complications, and success rates were compared between two groups. Results: Improvement of APD is higher in OP group ( p: 0.001). Improvement of DRF ( p: 0.713) and hydronephrosis ( p = 1.000), success ( p: 0.407) and complication rate ( p: 0.661) are comparable between two groups. Median hospital stay, postoperative analgesia requirement and blood loss was less in LP group, mean operative time was shorter in OP group ( p: 0.001). Conclusion: Pain complaints are greatly reduced after pyeloplasty in adult patients but the drainage of kidney, DRF and hydronephrosis does not improve as much as desired. Improvement of APD is better and median operative time is less in OP, intraoperative blood loss, hospital stay, and analgesic requirement is less in LP group in our study.

No abstract

Objective We aimed to determine factors responsible for chronic kidney disease (CKD) following nephrectomy for renal tumours. Methods A retrospective study was undertaken in patients underwent partial or radical nephrectomy due to kidney tumour between January 2015 and June 2020. Patients with eGFR above 60 ml/min/1.73m2 were included in the study. Demographic information, surgical features, eGFR values and some comorbidities of patients were recorded. The patients were evaluated for the development of CKD according to the CKD-EPI equation postoperatively. Results One hundred and sixty-six patients who underwent radical (n = 125) or partial (n = 41) nephrectomy were included to study. According to the logistic regression analysis, radical nephrectomy (adjusted OR 0.139 (95% CI 0.038–0.507), p = 0.003), age (adjusted OR 1.037 (95% CI 1.001–1.074), p = 0.045), preoperative proteinuria (adjusted OR 0.251 (95% CI 0.084–0.750) p = 0.013) and preoperative lower eGFR (adjusted OR 0.943 (95% CI 0.917–0.969) p < 0.001) were determined as independent predictor for development of CKD. Conclusions CKD is an important disease that causes morbidity and mortality. Age, type of surgery and preoperative eGFR and preoperative proteinuria are an independent risk factor for CKD development. Patients should be informed about this problem before surgery.

Aim: Overactive bladder (OAB) is a chronic, bothersome disease that decreases the quality of life and can be treated with antimuscarinic or β(3)-adrenergic agonist drugs, such as mirabegron. Myasthenia gravis (MG) is an autoimmune disease, in which neurotransmission is blocked by antibodies. Mirabegron is recommended as the first-line medical treatment for OAB compared with antimuscarinic drugs, which have several severe side effects. In this study, we assessed the efficacy of mirabegron in patients with MG and OAB. Methods: A total of 57 MG patients with OAB were included in this study. The participants received 50 mg mirabegron once daily and were followed up for 4 weeks. Subsequently, patients were evaluated using the International Consultation on Incontinence-Short Form and the "Overactive Bladder Symptom Score" (OABSS) and tasked to complete a 3-day micturition diary. Results: According to the 4-week follow-up results, the decrease in the OABSS scores following mirabegron administration was statistically significant (p<0.001). In addition, the frequency of daily micturition, nocturia, and need for a daily pad decreased dramatically (p=0.001, p=0.002, and p<0.001, respectively). In contrast, the average voiding volume increased significantly (p=0.001). Conclusions: Although they induce several side effects, antimuscarinic drugs are commonly used for OAB treatment. However, only a few autoimmune response-inducing drugs, with minimal side effects, are favored in MG comorbidity treatments. Thus, mirabegron is a promising candidate drug for the treatment of this type of comorbidity.

I read the prospective study titled 'Penile length and circumference dimensions: A large study in young Italian men' published in Andrologia with interest (Di Mauro et al., 2021). The study was conducted in Italy between January 2019 and 2020 among 4,685 patients. In the method part of the study, it was mentioned that the patients were informed about how to measure the penile length.